Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland

Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland

Neoadjuvant systemic therapy has now become the standard in early breast cancer management. Chemotherapy in combination with trastuzumab +/− pertuzumab targeted therapy can improve the rates of pathologic complete response (pCR) in patients with HER2-positive breast cancer. Achieving a pCR is consid...

Full description

Bibliographic Details
Main Authors: Agnieszka Irena Jagiełło-Gruszfeld, Magdalena Rosinska, Małgorzata Meluch, Katarzyna Pogoda, Anna Niwinska, Renata Sienkiewicz, Aleksander Grous, Paweł Winter, Zbigniew I. Nowecki
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
breast cancer
neoadjuvant chemotherapy
elderly
HER2
pathological complete response
safety
Online Access:https://www.mdpi.com/2072-6694/14/5/1218

Similar Items

Similar Items